2022 American Transplant Congress
Standard Induction with Basiliximab versus no Induction in Low Immunological Risk Kidney Transplant Recipients: Study Protocol for a Randomized Controlled Trial
1KFSHRC, RIYADH, Saudi Arabia, 2MOH, RIYADH, Saudi Arabia
*Purpose: To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC…2022 American Transplant Congress
Impact of Belatacept on Clinical Outcomes in Lung Transplant Patients with Antibody-Mediated Rejection
*Purpose: Antibody-mediated rejection (AMR) is cause of significant morbidity and mortality in lung transplant recipients (LTRs). An optimal therapeutic regimen is still lacking. Recent evidence…2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…2022 American Transplant Congress
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
*Purpose: Post-transplant immunosuppression with “everolimus + reduced dose tacrolimus” (Ev + Taclow) is reported to reduce the risk of viral infections compared to standard doses…2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…2022 American Transplant Congress
Impact of Target Tacrolimus Levels on BK Polyomavirus DNAemia and Allograft Rejection Among Pediatric Kidney Transplant Recipients
*Purpose: BK Polyomavirus (BK) DNAemia is a serious and common infectious complication after kidney transplant (KT). We evaluated the impact of targeting lower tacrolimus levels…2022 American Transplant Congress
Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for T2 Hepatocellular Carcinoma and May Allow for Decreased Mortality
*Purpose: Prior studies have suggested that induction therapy leads to worse outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study evaluated the impact…2022 American Transplant Congress
Impact of Glecaprevir/Pibrentasvir on Tacrolimus Concentration in Solid Organ Transplant Recipients with or without Triazole Antifungal Therapy
*Purpose: Provide guidance on tacrolimus (TAC) dose adjustments during glecaprevir/pibrentasvir (GLE/PIB) initiation and discontinuation in patients on triazole antifungals by comparing changes in TAC concentration-dose…2022 American Transplant Congress
A Low Immuknow Level but Behold….pAMR1(H+) Rejection
Tampa General Hospital, Tampa, FL
*Purpose: PURPOSE: The purpose of this study is to evaluate the mechanism of pAMR1(H+) rejection in heart transplant recipients with low ImmuKnow levels (ATP2022 American Transplant Congress
Association Between Maintenance Immunosuppressive Regimens And Covid-19 Mortality In Kidney Transplant Recipients
*Purpose: Kidney transplant recipients (KTR) are at increased risk of mortality from COVID-19. We conducted a cohort study among KTR from the French Solid Organ…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 138
- Next Page »